Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Estats Units - anglès - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 500 mg in 2 ml

Estats Units - anglès - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including postvascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection, are not indicated in uncomplicated initial episodes of urinary tract infec

Israel - anglès - Ministry of Health

lapidot medical import and marketing ltd - amikacin as sulfate - solution for infusion - amikacin as sulfate 10 mg / 1 ml - amikacin - amikacin b braun is indicated in the short-term treatment of gram-negative organisms, including pseudomonas and some gram-positive organisms.sensitive gram-negative organisms include; pseudomonas aeruginosa, escherichia coli., indole-positive and indole-negative proteus spp., klebsiella, enterobacter and serratia spp., minea-herralae, citrobacter freundii, salmonella, shigella, acinetobacter and providencia spp.the principal gram-positive organism sensitive to amikacin is staphylococcus aureus, including some methicillin-resistant strains. amikacin b braun has some activity against other gram-positive organisms including certain strains of streptococcus pyogenes, enterococci and diplococcus pneumoniae.

Israel - anglès - Ministry of Health

lapidot medical import and marketing ltd - amikacin as sulfate - solution for infusion - amikacin as sulfate 5 mg / 1 ml - amikacin - amikacin b braun is indicated in the short-term treatment of gram-negative organisms, including pseudomonas and some gram-positive organisms.sensitive gram-negative organisms include; pseudomonas aeruginosa, escherichia coli., indole-positive and indole-negative proteus spp., klebsiella, enterobacter and serratia spp., minea-herralae, citrobacter freundii, salmonella, shigella, acinetobacter and providencia spp.the principal gram-positive organism sensitive to amikacin is staphylococcus aureus, including some methicillin-resistant strains. amikacin b braun has some activity against other gram-positive organisms including certain strains of streptococcus pyogenes, enterococci and diplococcus pneumoniae.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - amikacin -

Canadà - anglès - Health Canada

sandoz canada incorporated - amikacin (amikacin sulfate) - liquid - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Canadà - anglès - Health Canada

marcan pharmaceuticals inc - amikacin (amikacin sulfate) - solution - 500mg - amikacin (amikacin sulfate) 500mg - aminoglycosides

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium metabisulfite; sodium citrate dihydrate; water for injections - amikacin ajs injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin ajs injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.